AnaptysBio Inc (ANAB)
26.58
+0.24
(+0.91%)
USD |
NASDAQ |
May 03, 16:00
26.57
-0.01
(-0.04%)
After-Hours: 20:00
AnaptysBio Enterprise Value: 320.46M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 320.46M |
| May 02, 2024 | 314.04M |
| May 01, 2024 | 305.47M |
| April 30, 2024 | 260.51M |
| April 29, 2024 | 179.15M |
| April 26, 2024 | 171.12M |
| April 25, 2024 | 114.12M |
| April 24, 2024 | 124.82M |
| April 23, 2024 | 122.41M |
| April 22, 2024 | 135.26M |
| April 19, 2024 | 140.88M |
| April 18, 2024 | 139.81M |
| April 17, 2024 | 183.70M |
| April 16, 2024 | 180.22M |
| April 15, 2024 | 178.35M |
| April 12, 2024 | 216.89M |
| April 11, 2024 | 270.95M |
| April 10, 2024 | 202.43M |
| April 09, 2024 | 185.31M |
| April 08, 2024 | 162.29M |
| April 05, 2024 | 173.26M |
| April 04, 2024 | 179.15M |
| April 03, 2024 | 163.63M |
| April 02, 2024 | 166.84M |
| April 01, 2024 | 179.69M |
| Date | Value |
|---|---|
| March 28, 2024 | 211.80M |
| March 27, 2024 | 181.29M |
| March 26, 2024 | 187.18M |
| March 25, 2024 | 173.80M |
| March 22, 2024 | 189.05M |
| March 21, 2024 | 263.45M |
| March 20, 2024 | 249.80M |
| March 19, 2024 | 231.87M |
| March 18, 2024 | 229.20M |
| March 15, 2024 | 236.69M |
| March 14, 2024 | 240.71M |
| March 13, 2024 | 269.88M |
| March 12, 2024 | 306.54M |
| March 11, 2024 | 234.01M |
| March 08, 2024 | 272.82M |
| March 07, 2024 | 268.27M |
| March 06, 2024 | 291.29M |
| March 05, 2024 | 287.01M |
| March 04, 2024 | 304.61M |
| March 01, 2024 | 285.99M |
| February 29, 2024 | 288.12M |
| February 28, 2024 | 295.56M |
| February 27, 2024 | 313.12M |
| February 26, 2024 | 312.85M |
| February 23, 2024 | 297.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-141.71M
Minimum
Nov 08 2019
1.692B
Maximum
May 29 2019
290.07M
Average
238.91M
Median
Mar 14 2022
Enterprise Value Benchmarks
| XOMA Corp | 258.75M |
| Fate Therapeutics Inc | 87.73M |
| Ocular Therapeutix Inc | 796.15M |
| Apellis Pharmaceuticals Inc | 5.465B |
| Sutro Biopharma Inc | -76.95M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.21M |
| Revenue (Quarterly) | 9.005M |
| Total Expenses (Quarterly) | 43.80M |
| EPS Diluted (Quarterly) | -1.59 |
| Profit Margin (Quarterly) | -468.8% |
| Earnings Yield | -22.87% |
| Normalized Earnings Yield | -22.87 |